Many breast cancer patients can skip chemo, confirms landmark study


Many breast cancer patients can skip chemo, confirms landmark study

Findings of the past have indicated that women who met these criteria and scored below ten on the index test could safely skip chemotherapy without raising their rate of recurrence, however, those above 25 would nearly always be advised to use chemotherapy as a necessary treatment to lower risk of recurrence.

A study presented by the American Society of Clinical Oncology on Sunday found that about 70% of women diagnosed with the early stages of a common type of breast cancer may not need chemotherapy as part of their treatment.

Dr Epstein, a clinical oncologist at Memorial Sloan Kettering Cancer Centre in NY, said the two studies show "the anti-inflammatory benefits of a relatively cheap, well-tolerated supplement".

"The results of PREOPANC trial certainly strengthens the argument for it", said Chang. He said "Oncologists have been waiting for these results, it will affect practice on Monday morning".

Doctors at the University of Texas analysed the progress of 1,307 patients with a range of cancers including breast, gynecologic and gastrointestinal. "It's a great news story".

"However, this is a small study so more research is needed before we have clear-cut answers on the benefits of fish oil for easing pain from breast cancer treatment".

The hormone treatment is usually taken for between five to 10 years after surgery.

"Chemotherapy is not without its side effects, but it's still a discussion that a woman has to have with her physician", said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital.

The findings suggest that thousands of women could one day forgo a treatment with long-term health ramifications without risking the spread of cancer. The money was used to pay for the gene test, which costs more than $4,000 per person. Similar tests including one called MammaPrint also are widely used. This data adds to findings from a TAILORx analysis published in 2015 that provided prospective evidence that the gene expression test could identify women with a low risk of recurrence who could be spared chemotherapy.

The study was extensive so patients who fit in this new category should be very confident with their course of treatment, even if it's without chemotherapy. "I sort of viewed chemo as extra insurance", she said.

Adine Usher, 78, who lives in Hartsdale, New York, joined the study 10 years ago at Montefiore and was randomly assigned to the group given chemo.

"I was somewhat relieved".

"I lost my hair". Now, thanks to this new study, doctors can safely say that their hunch was correct all along. "I'm a firm believer in medical research".